Literature DB >> 23535161

Cutting edge in myasthenia gravis.

Sonia Berrih-Aknin, Miriam C Souroujon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23535161     DOI： 10.1016/j.autrev.2013.03.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


× No keyword cloud information.
  3 in total

1.  The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.

Authors:  Elena Cortés-Vicente; Ricard Rojas-Garcia; Jordi Díaz-Manera; Luis Querol; Carlos Casasnovas; Antonio Guerrero-Sola; José Luis Muñoz-Blanco; José Eulalio Bárcena-Llona; Celedonio Márquez-Infante; Julio Pardo; Eva María Martínez-Fernández; Mercedes Usón; Pedro Oliva-Nacarino; Teresa Sevilla; Isabel Illa
Journal:  Ann Clin Transl Neurol       Date:  2018-04-14       Impact factor: 4.511

2.  Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice.

Authors:  Huan Luo; Shanshan Xie; Chao Ma; Wenqiang Zhang; Carsten Tschöpe; Xianen Fa; Jingliang Cheng; Jing Cao
Journal:  Front Neurol       Date:  2019-01-15       Impact factor: 4.003

3.  Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.

Authors:  David Reyes-Leiva; Joaquín López-Contreras; Esther Moga; Francesc Pla-Juncà; Elionor Lynton-Pons; Ricardo Rojas-Garcia; Janina Turon-Sans; Luis Querol; Montse Olive; Rodrigo Álvarez-Velasco; Marta Caballero-Ávila; Álvaro Carbayo; Ana Vesperinas-Castro; Pere Domingo; Isabel Illa; Eduard Gallardo; Elena Cortés-Vicente
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.